Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001654954-24-015473
Filing Date
2024-12-12
Accepted
2024-12-12 19:58:31
Documents
1
Period of Report
2024-12-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT section16.html 4  
1 PRIMARY DOCUMENT section16.xml 4 7511
  Complete submission text file 0001654954-24-015473.txt   9313
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Issuer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Business Address
Doogan Declan (Reporting) CIK: 0001704234 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34600 | Film No.: 241546444